. 2018 May;58(5):636–647. doi: 10.1165/rcmb.2017-0292OC

Table 1.

Blood Cell Indices for Berkeley-Hemizygous (Control) Versus Berkeley–Sickle Cell Disease Mice with/without Treatments

	BERK-Hemi Placebo (n = 13–30)	BERK-SCD
		Placebo	BAY 54-6544	BAY 41-8543
		(n = 10–17)	(n = 6–8)	(n = 7–8)
Hct, %	36.7 ± 1.3	18.7 ± 0.8^*	17.3 ± 1.2^*	18.1 ± 2.1^*
Hgb, g/dL	10.7 ± 0.3	5.1 ± 0.2^†	4.8 ± 0.3^†	4.9 ± 0.5^†
MCV, fL	34.2 ± 1.7	39.6 ± 0.9^*	38.2 ± 0.4^‡	37.7 ± 0.5^‡
RDW, %	20.7 ± 0.3	28.0 ± 0.7^*	27.7 ± 0.6^†	26.9 ± 0.4^‡
Retic, 10⁶	6.4 ± 1.9	46.9 ± 7.1^*	46.1 ± 0.9^*	39.6 ± 2.1^‡
WBC, 10³	5.9 ± 0.9	22.9 ± 4.0^†	21.6 ± 4.7^‡	16.9 ± 7.4^§
PLT, 10³	566.1 ± 52.8	367.8 ± 40.8^†	257.3 ± 75.6^‡	308.6 ± 53.7

Definition of abbreviations: BERK = Berkeley; Hct = hematocrit; hemi = hemizygous; Hgb = total hemoglobin; MCV = mean corpuscular volume; PLT = platelets; RDW = red blood cell distribution width; Retic = reticulocytes; SCD = sickle cell disease; WBC = leukocytes.

Values are ± SEM using unpaired Student’s t test. Red cell indices for control (BERK-Hemi) and SCD mice with/out soluble guanylate cyclase modulators.

P < 0.0001 versus control.

^{^†}

P < 0.0005 versus control.

^{^‡}

P < 0.05 versus control.

^{^§}

P < 0.005 versus control.